Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer.
Publication/Presentation Date
5-1-2011
Abstract
Prostatic adenocarcinomas are reliant on androgen receptor (AR) activity for survival and progression. Therefore, first-line therapeutic intervention for disseminated disease entails the use of AR-directed therapeutics, achieved through androgen deprivation and direct AR antagonists. While initially effective, recurrent, 'castrate-resistant' prostate cancers arise, for which there is no durable means of treatment. An abundance of clinical study and preclinical modeling has led to the revelation that restored AR activity is a major driver of therapeutic failure and castrate-resistant prostate cancer development. The mechanisms underpinning AR reactivation have been identified, providing the foundation for a new era of drug discovery and rapid translation into the clinic. As will be reviewed in this article, these creative new ways of suppressing AR show early promise.
Volume
6
Issue
3
First Page
483
Last Page
493
ISSN
1744-6651
Published In/Presented At
Knudsen, K. E., & Kelly, W. K. (2011). Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert review of endocrinology & metabolism, 6(3), 483–493. https://doi.org/10.1586/eem.11.33
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
22389648
Department(s)
Administration and Leadership
Document Type
Article